State Key Laboratory of Oncogenes and Related Genes (SKLORG), affiliated with Shanghai Cancer Institute and Shanghai Jiao Tong University, was approved to set up by the National Planning Commission of China in 1985. It was accepted by the state and formally opened in 1987. SKLORG now has 66 faculty members, including three academicians of the Chinese Academy of Engineering, one member of the China National Funds for Distinguished Yong Scientists, one member of Cheung Kong Scholars Programme, and one member of the China National Plan of "One Thousand Talented Scholars". In recent ten years, SKLORG was granted by more than 30 national projects. The Laboratory has won 18 prizes from the National Government and Shanghai Municipality including two prizes of the National Science and Technology Awards, obtained 64 national warranted-patents and four international warranted-patents, published more than 400 peer-reviewed research articles, and trained 121 graduate students including 47 Ph.D. candidates. SKLORG, with an overall floorage of 5,300 square meters, is provided with 36 sets of state-of-the-art experimental equipments including ultra high speed flow cytometer (MoFlo XDP), live cell station (IX81), laser microdissection (Leica AS/LMD), DIGE, ABI7900, HPLC (Agilent 1200).

Cancer stem cell and tumor microenvironment: the objectives are to identify specific markers of cancer stem cell in liver cancer, to establish the technology of separation of liver cancer stem cell from primary liver cancer, to explore the molecular mechanisms of bone marrow stem cells in the development and progression of human hepatocellular carcinoma, to systematically investigate the regulatory mechanism of signaling molecules, in particular, immune-related factors in liver cancer stem cell, and to reveal the roles of tumor microenvironment in liver cancer. Cancer translational medicine: the purposes are to establish the non-viral vector system for cancer gene therapy, to establish liposome drug delivery systems targeting liver cancer cells, and to develop therapeutic monoclonal antibodies for cancer therapy.